HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
HilleVax, Inc. (HLVX)
Company Research
Source: GlobeNewswire
$189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Results As of September 30, 2024 and December 31, 2023, the company had cash, cash equivalents and marketable securities totaling $189.3 million and $303.5 million, respectively. Research and development expenses for the third quarter 2024 were $20.2 million, compared to $27.3 for the third quarter 2023. The decrease was primarily due to lower clinical development costs. General and administrative expenses for the third qu
Show less
Read more
Impact Snapshot
Event Time:
HLVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HLVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HLVX alerts
High impacting HilleVax, Inc. news events
Weekly update
A roundup of the hottest topics
HLVX
News
- Moderna's norovirus vaccine enters Phase III trials in the UK [Yahoo! Finance]Yahoo! Finance
- What Makes HilleVax (HLVX) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- HilleVax, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by HilleVax (HLVX)Accesswire
- Levi & Korsinsky Investigates Possible Securities Fraud Violations by HilleVax, Inc. (HLVX)Accesswire
- Investors who lost money on HilleVax, Inc. should contact Levi & Korsinsky about an ongoing investigation - HLVXAccesswire
HLVX
Earnings
- 8/8/24 - Miss
HLVX
Sec Filings
- 11/7/24 - Form 10-Q
- 11/7/24 - Form 8-K
- 10/16/24 - Form 8-K
- HLVX's page on the SEC website